Abstract 397P
Background
In the Nordics, new treatments have emerged, offering targeted therapies tailored to the specific pathophysiology of breast cancer (BC). These therapies are more effective with fewer side effects than conventional chemotherapy. It's crucial to monitor treatment trends, effectiveness, patient selection, and safety closely. The current study aims to study usability and coverage of real-world data among patients with BC in Norway and Denmark with focus on biomarkers in de novo metastatic BC (mBC).
Methods
BC patients were identified in national administrative registers in Denmark and Norway from January 1, 2015 to December 31, 2020 and followed until death or end of follow-up, i.e., December 31, 2021. Patients were categorized according to stage and biomarker status (hormone receptor (HR) and HER2). Descriptive statistics and one-year survival analyses based on Kaplan-Meier were carried out stratified per country, stage and biomarker status.
Results
In total, 51,641 patients with BC were identified (Denmark: 29,392; Norway=22,249), of which 1,988 (3.8%) had mBC at time of diagnosis (Denmark=946 (3.2%); Norway=1,042 (4.7%)). The age at time of diagnosis of mBC was 68.4 in Denmark and 64.4 in Norway. The number and proportions with HR and HER2 combinations in Denmark and Norway, respectively, were HR+/HER2+ 103 (11%) and 58 (5.6%), HR+/HER2- 608 (64%) and 426 (41%), HR-/HER2+ 51 (5%) and 70 (6.7%), HR-/HER2- (i.e., triple negative) 101 (11%) and 102 (10%), not tested 83 (9%) and 386 (37%). One-year survival was highest among mBC patients with HR+/HER2+ status (Denmark= 0.73 (95% confidence interval (CI), 0.65-0.82); Norway= 0.86 (95% CI, 0.80-0.95)) and lowest among those with triple negative mBC (Denmark= 0.52 (95% CI, 0.44-0.63); Norway=0.51 (95% CI, 0.41-0.62)) as expected.
Conclusions
Results are overall in agreement between the two countries with high coverage. This unique data will later be combined with treatment records and becomes highly valuable for real-world evidence studies of targeted treatments in patients with BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Quantify Research.
Funding
Has not received any funding.
Disclosure
J. Liseth Hansen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. M. Johnsen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. F. Fischer: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. O. Ström: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. T. Kopp: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple.
Resources from the same session
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
376P - Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast cancer patients
Presenter: Rana El-Shewy
Session: Poster session 15
377P - Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Presenter: Niels Guchelaar
Session: Poster session 15
378P - Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Presenter: Duan Yang
Session: Poster session 15
379P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Presenter: Luca Visani
Session: Poster session 15
381P - Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
Presenter: Kelsey Natsuhara
Session: Poster session 15
382P - Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study
Presenter: Jiaxuan Liu
Session: Poster session 15